Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
agricultural and biological sciences
Pharmacokinetics of melarsoprol in uninfected vervet monkeys
Acta Tropica, Volume 58, No. 1, Year 1994
Notification
URL copied to clipboard!
Description
The level of the trypanocidal drug melarsoprol was determined in serum and cerebrospinal fluid (CSF) of six healthy vervet monkeys after intravenous application of the drug following a standard treatment schedule and a recently suggested alternative protocol. The maximum serum levels measured were about 3 μg/ml. A three-compartment model was used to analyze the serum data. The mean residence time calculated for melarsoprol in serum was 18 h, the volume of distribution was 3.6 l/kg and the clearance was 3.5 ml/min*kg. In the CSF the drug levels were generally very low, not exceeding 55 ng/ml, and the adaptation of the drug levels was found to be very slow. The comparison of the drug concentrations required to eliminate trypanosomes in vitro and the drug concentrations reached in the CSF during treatment revealed that the latter might be insufficient in some cases to eliminate all trypanosomes from this site. The peak serum levels during alternative application of the drug were lower compared to those during empirical treatment. No evidence for drug cumulation in the body was found. The results of this study are compared with recent pharmacokinetic data from human patients, and discussed in the context of the problem of relapses and reactive encephalopathy occurring after treatment of sleeping sickness. © 1994.
Authors & Co-Authors
Burri, Christian
Switzerland, Allschwil
Swiss Tropical and Public Health Institute Swiss Tph
Onyango, James D.
Kenya
Kenya Trypanosomiasis Research Institute Ketri
Auma, Joanna Eseri
Kenya
Kenya Trypanosomiasis Research Institute Ketri
Burudi, E. M.E.
Kenya
Kenya Trypanosomiasis Research Institute Ketri
Brun, Reto
Switzerland, Allschwil
Swiss Tropical and Public Health Institute Swiss Tph
Statistics
Citations: 27
Authors: 5
Affiliations: 2
Identifiers
Doi:
10.1016/0001-706X(94)90120-1
ISSN:
0001706X